PMID- 37874694 OWN - NLM STAT- MEDLINE DCOM- 20240205 LR - 20240211 IS - 1535-4989 (Electronic) IS - 1044-1549 (Print) IS - 1044-1549 (Linking) VI - 70 IP - 2 DP - 2024 Feb TI - P300/CBP Regulates HIF-1-Dependent Sympathetic Activation and Hypertension by Intermittent Hypoxia. PG - 110-118 LID - 10.1165/rcmb.2022-0481OC [doi] AB - Obstructive sleep apnea (OSA), a widespread breathing disorder, leads to intermittent hypoxia (IH). Patients with OSA and IH-treated rodents exhibit heightened sympathetic nerve activity and hypertension. Previous studies reported transcriptional activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (Nox) by HIF-1 (hypoxia-inducible factor-1) contribute to autonomic dysfunction in IH-treated rodents. Lysine acetylation, regulated by KATs (lysine acetyltransferases) and KDACs (lysine deacetylases), activates gene transcription and plays an important role in several physiological and pathological processes. This study tested the hypothesis that acetylation of HIF-1alpha by p300/CBP (CREB-binding protein) (KAT) activates Nox transcription, leading to sympathetic activation and hypertension. Experiments were performed on pheochromocytoma-12 cells and rats treated with IH. IH increased KAT activity, p300/CBP protein, HIF-1alpha lysine acetylation, HIF-1 transcription, and HIF-1 binding to the Nox4 gene promoter in pheochromocytoma-12 cells, and these responses were blocked by CTK7A, a selective p300/CBP inhibitor. Plasma norepinephrine (index of sympathetic activation) and blood pressures were elevated in IH-treated rats. These responses were associated with elevated p300/CBP protein, HIF-1alpha stabilization, transcriptional activation of Nox2 and Nox4 genes, and reactive oxygen species, and all these responses were absent in CTK7A-treated IH rats. These findings suggest lysine acetylation of HIF-1alpha by p300/CBP is an important contributor to sympathetic excitation and hypertension by IH. FAU - Wang, Ning AU - Wang N AD - Institute for Integrative Physiology and Center for Systems Biology of O2 Sensing, The University of Chicago, Chicago, Illinois. FAU - Su, Xiaoyu AU - Su X AD - Institute for Integrative Physiology and Center for Systems Biology of O2 Sensing, The University of Chicago, Chicago, Illinois. FAU - Sams, David AU - Sams D AD - Institute for Integrative Physiology and Center for Systems Biology of O2 Sensing, The University of Chicago, Chicago, Illinois. FAU - Prabhakar, Nanduri R AU - Prabhakar NR AD - Institute for Integrative Physiology and Center for Systems Biology of O2 Sensing, The University of Chicago, Chicago, Illinois. FAU - Nanduri, Jayasri AU - Nanduri J AUID- ORCID: 0000-0003-3984-7447 AD - Institute for Integrative Physiology and Center for Systems Biology of O2 Sensing, The University of Chicago, Chicago, Illinois. LA - eng GR - P01 HL144454/HL/NHLBI NIH HHS/United States GR - P01-HL144454/NH/NIH HHS/United States PT - Journal Article PL - United States TA - Am J Respir Cell Mol Biol JT - American journal of respiratory cell and molecular biology JID - 8917225 RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - K3Z4F929H6 (Lysine) RN - EC 2.3.1.48 (p300-CBP Transcription Factors) RN - 0 (Hif1a protein, rat) SB - IM CIN - Am J Respir Cell Mol Biol. 2024 Feb;70(2):87-88. PMID: 38109691 MH - Animals MH - Rats MH - *Adrenal Gland Neoplasms MH - *Hypertension MH - Hypoxia/metabolism MH - Hypoxia-Inducible Factor 1, alpha Subunit MH - Lysine MH - p300-CBP Transcription Factors/genetics/metabolism MH - *Pheochromocytoma MH - *Sleep Apnea, Obstructive/complications PMC - PMC10848695 OTO - NOTNLM OT - histone acetylases OT - hypoxia inducible factor-1 OT - intermittent hypoxia OT - obstructive sleep apnea OT - p300/CBP EDAT- 2023/10/24 18:42 MHDA- 2024/02/02 06:43 PMCR- 2024/10/24 CRDT- 2023/10/24 12:39 PHST- 2024/10/24 00:00 [pmc-release] PHST- 2024/02/02 06:43 [medline] PHST- 2023/10/24 18:42 [pubmed] PHST- 2023/10/24 12:39 [entrez] AID - 10.1165/rcmb.2022-0481OC [doi] PST - ppublish SO - Am J Respir Cell Mol Biol. 2024 Feb;70(2):110-118. doi: 10.1165/rcmb.2022-0481OC.